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Enhanced nitric oxide synthesis in uremia: Implications for platelet
dysfunction and dialysis hypotension. Nitric oxide (NO), a potent
vasodilator which also inhibits platelet adhesion and aggregation, is
generated by endothelial cells and platelets from its precursor L-argi-
nine. Since N-monomethyl-L-arginine (L-NMMA), an inhibitor of NO
synthesis, normalizes the prolonged bleeding time of uremic rats, it has
been suggested that bleeding associated with uremia was due to an
excessive NO formation. With the present study we sought to evaluate
whether in patients with chronic renal failure—like in uremic rats—
defective platelet aggregation were associated with excessive formation
of NO and whether uremic plasma promotes NO synthesis by cultured
vascular endothelium. Data indicated that plasma L-arginine was higher
in uremics than in controls, uremic platelets generated more NO than
control platelets, and intraplatelet levels of cGMP (the NO second
messenger) were also higher in uremic than in control platelets.
Moreover, uremic plasma potently induced NO synthesis by cultured
endothelial cells, a phenomenon which was further amplified by adding
to uremic plasma endotoxin and interferon y. Increased NO biosynthe-
sis may contribute to platelet dysfunction and possibly other manifes-
tations of uremic syndrome, including hemodialysis hypotension.
Bleeding is a well-known complication of uremia [1] attrib-
uted in the past to the retention in uremic plasma of dialyzable
factor(s) that suppress platelet adhesion and aggregation [2, 3].
Recent animal experiments [4] have suggested that bleeding
tendency in uremia is related to an excessive formation of nitric
oxide (NO), an endogenous vasoactive molecule [5] which also
inhibits platelet function [6—8]. Thus, prolonged bleeding time,
the best marker of uremic bleeding, completely normalizes by
giving uremic rats N-monomethyl-L-arginine, a competitive
inhibitor of NO synthesis [4]. NO is mainly formed in endothe-
hal cells by the action of NO-forming enzyme of which two
subtypes have been identified and recently cloned: one consti-
tutively expressed mainly in vascular endothelium [9, 10] and
neurons [11], the other induced by cytokines [12] and endotoxin
[9, 13].
The first aim of the present study was to establish whether in
patients with chronic renal failure, as in uremic rats, defective
platelet aggregation was associated with excessive formation of
NO. We additionally reasoned that, if NO were increased in
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uremia, this could be relevant to the complex manifestations of
"uremic syndrome," since nitric oxide is a potent vasorelaxant
[5] and acts as a neurotransmitter [14]. Therefore, the second
aim of the present study was to establish whether uremic
plasma promotes NO synthesis by cultured vascular endothe-
hum, and whether this was due to an activation of the consti-
tutive or the inducible form of the enzyme.
Methods
Subjects
Two groups of subjects participated in this study: (1) seven
patients with end-stage renal failure on regular hemodialysis (4
men and 3 women, age 40 to 81 years, serum creatinine 868.5
218.5 smolIhiter), and (2) eight healthy volunteers (4 men and 4
women, age 23 to 80 years). All gave informed consent accord-
ing to the locally approved procedure and to the Declaration of
Helsinki. The patients had a history of bleeding symptoms and
variably prolonged skin bleeding time (7.30 to 12 mm), hema-
tocrit values between 24 and 32%. They were undergoing
regular hemodialysis with a cuprophan membrane dialyzer
according to a schedule of 12 hours per square meter of body
surface per week, in three weekly sessions. Venous blood was
collected directly in plastic tubes containing heparin (10 U/mI).
In uremic patients blood was drawn immediately before a
regular dialysis session.
Experimental design
We first evaluated whether in patients with chronic renal
failure the NO precursor L-arginine was increased. To this
purpose plasma levels of L-arginine were measured both in
uremic patients immediately before dialysis and in healthy
volunteers.
We also investigated whether defective platelet aggregation
in patients with chronic renal failure was associated with
increased synthesis of nitric oxide. Heparinized blood was
centrifuged at 200 x g for 15 minutes at room temperature to
obtain platelet rich plasma (PRP). Platelet aggregation was
performed on PRP sample by the turbidimetric method of Born
and Cross [15], using a dual-channel aggregometer ELVI 140
(Elvi Logos, Milan, Italy). PRP (250 sl) was stirred for one
minute at 37°C before the addition of collagen. The aggregation
was followed for three minutes on a chart recorder. The
threshold aggregating concentration (TAC), defined as the
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lowest concentration of agonist that caused irreversible aggre-
gation within three minutes after its addition to PRP, was
determined. For each subject the dose-response to collagen was
studied and the lowest concentration of stimulant that caused
maximal aggregation determined. Platelet NO synthesis was
studied in PRP by two means: (1) by studying the conversion of
[3H]L-arginine to [3H1L-citrulline, and (2) by measuring intra-
cellular levels of the NO second messenger, cGMP [71. PRP
was studied twice, in resting conditions (basal) or after stimu-
lation with collagen at the dose that induced maximal aggrega-
tion. To evaluate the conversion of [3HJL-arginine to [3H]L-
citrulline, aliquots (250 Ml) of PRP were preincubated at 37°C
for 1.5 hours with 0.5 jsCi [3H]L-arginine (New England Nu-
clear, Boston, Massachusetts, USA; 56.4 Cilmmol) to allow
intracellular incorporation of the labeled amino acid. Thereafter
samples were stirred at 1000 rpm for 10 minutes in the presence
of collagen or the vehicle. Aliquots of PRP were incubated with
[3H]L-arginine in the presence of 300 MM N-monomethyl-L-
arginine (LNMMA, Calbiochem, San Diego, California, USA),
a specific inhibitor of NO formation from L-arginine [16]. Two
hundred and fifty microliter aliquots of platelet poor plasma
(PPP) were also incubated with [3H]L-arginine and used as
blanks. All incubations were stopped by adding one volume of
ice-cold 15% trichloroacetic acid (TCA). To evaluate intracel-
lular cGMP, aliquots (250 Ml) of PRP were stirred for four
minutes at 37°C in the presence of collagen or the vehicle.
Thereafter, 1 mM isobutylmethylxantine (IBMX, Sigma Chem-
ical, St Louis, Missouri, USA) was added to inhibit phospho-
diesterase, and the stirring was continued for three minutes. In
these conditions IBMX had no effect on collagen induced
aggregation (data not shown). Incubations were stopped by
addition of 100 M1 of 20% HCIO4, and samples were then
neutralized with K3P04 (1.08 M, 200 Ml) and centrifuged at
12,000 x g for two minutes. Supernatant was assayed for cGMP
content by a specific radioimmunoassay (New England Nucle-
ar). Equal amounts of PPP were also assayed to evaluate
plasma cOMP levels. For each subject intraplatelet cGMP was
calculated by subtracting cGMP plasma levels to values ob-
tained in PRP.
To investigate whether uremic plasma contains endogenous
substances which increase vascular NO synthesis, human um-
bilical vein endothelial cells (HUVEC) were exposed in vitro to
plasma from control and uremic subjects. Synthesis of NO by
HUVEC was evaluated by measuring the conversion of [3HIL-
arginine to [3H]L-citrulline. HUVEC were washed twice with
phosphate buffer saline (PBS) and incubated for 24 hours with 1
ml of heparinized plasma containing [3H]L-arginine (0.5 MCi).
Incubation was stopped by adding one volume of ice-cold 15%
TCA. Since tumor necrosis factor c (TNFa) is a potent inducer
of inducible NO-synthase enzyme [12, 17], levels of TNFa were
determined in the plasma from controls and uremics by using an
enzyme-linked immunoadsorbent assay (ELISA, Amersham,
Buckinghamshire, UK). In separate dishes endotoxin lipopoly-
saccharide (LPS; 1 jzg/ml, Difco Laboratories, Detroit, Michi-
gan, USA) and interferon y (IFN7, 150 U/ml, Institut Roussel
Uclaf, Paris, France) were added to control and uremic plasma
to stimulate inducible endothelial cell NO-synthase [9]. One
milliliter aliquots of plasma from each subjects containing
[3H]L-arginine (0.5 jsCi) were also incubated without cells and
used as blanks.
Plasma L-arginine measurement
Heparinized blood was centrifuged at 2000 x g for 15 minutes
to separate plasma. L-arginine was analyzed by high perfor-
mance liquid chromatography (HPLC) with fluorescence detec-
tion after pre-column derivatization with o-phthaldialdheide
(OPA) according to the method of Jones and Gilligan [18] with
minor modifications. Briefly, 10 M1 of a 100 g/ml homoserine
solution (internal standard) was added to 200 M1 of plasma and
after vortex mixing, 25 M1 of sample were mixed vigorously with
acetonitrile (75 Ml). Following centrifugation at 10,000 x g for
three minutes, 10 M1 aliquots were subjected to OPA (Fluor-
aldehyde, Pierce, Rockford, Illinois, USA) derivatization and
analyzed. The HPLC system consisted of a model 334 liq-
uid chromatograph (Beckman, Fullerton, California, USA)
equipped with a programmable fluorescence detector (Chrom-
pack, Middelburg, Netherlands) set to an excitation wavelength
of 338 nm and an emission wavelength of 425 nm. Samples were
chromatographed on a C-l8 reverse-phase column (Chromsep S
Mm, 200 mm x 3 mm I.D., Chrompack) using a linear gradient
from 100% solvent A (0.025 M KH2PO4 at pH 7.2/CH3OH: 75/25
plus 0.8 mI/liter tetrahydrofuran) to 25% solvent B (CH3OH) in
10 minutes at a flow rate of 0.5 ml/min.
Determination of [3H]L-citrulline formation from [3H]L-
arginine
TCA-treated samples were centrifuged at 10,000 x g to
precipitate proteins. Thereafter, supernatant was extracted five
times with one volume of water-saturated ether, vacuum lyoph-
ilized and resuspended in 2 ml N-2-hydroxyethylpiperazine-N'-
2-ethanesulfonic acid (HEPES, Merck, Darmstadt, Germany),
pH 5.5, and applied to 2 ml wet bed volumes of Dowex AG 50
WX-8 (100 to 200 mesh, Bio-Rad, Richmond, California, USA)
(Lit form), followed by 2 ml of water. [3H]L-citrulline was
quantitated by liquid scintillation counting in the 4-ml column
effluent. Results were expressed as nmoles (or pmoles) [3H]L-
citrulline by correcting data in CPM for the specific activity of
[3H]L-arginine, calculated on the basis of plasma endogenous
content of L-arginine as measured by HPLC. Recovery of
['4C]L-citrulline (New England Nuclear, 53.7 mCiimmol) after
cation exchange chromatography, determined by addition of
['4C]L-citrulline to samples before TCA treatment was over
60%. Thin layer chromatography (TLC) was utilized to identify
the product of cation exchange chromatography, as described
[17].
Cell isolation and culture
Human endothelial cells (HUVEC) were obtained from um-
bilical veins according to the method of Jaffé and coworkers
[19]. Cells were grown in medium 199 (Gibco, Grand Island,
New York, New York, USA) supplemented with 20% newborn
calf serum (Gibco) and antibiotics and were used at the first
passage.
Statistical analysis
Results are expressed as the mean SD. Data on plasma
L-arginine and TNFa as well as collagen doses and platelet
count were analyzed by the nonparametric Mann-Whitney U
test. Data on NO synthesis by platelets and endothelial cells in
vitro were analyzed by a Between-Within Subjects Analysis of
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Variance (ANOVA) and subsequently by the Tukey multiple
comparison procedure, using the SAS/STAT software [20].
Analysis of [3H]L-citrulline and cGMP data was performed
after a normalizing transformation (natural logarithms) of the
original values to minimize correlation between the mean and
the variance. Linear regression analysis was performed to
correlate platelet NO and cGMP levels. Statistical level of
significance was defined as P <0.05.
Results
Plasma levels of L-arginine and TNFa
Plasma levels of the NO precursor L-arginine, measured by
HPLC, were significantly higher in patients with chronic renal
failure than in healthy volunteers (68.3 18.9, N = 7, vs. 39.8
12.0 mol/liter, N = 8, P = 0.004). The gradient profile for
amino acid separation was specifically developed to obtain a
complete separation of L-arginine (retention time, Tr: 14.8
mm), citrulline (Tr: 12.9 mm) and ornithine (Tr: 49.7 mm) from
the other amino acids. Since dimethylarginine may accumulate
in uremic plasma [21], a baseline separation between L-arginine
and dimethylarginine (Tr: 16.8 mm) was achieved to avoid
possible overestimation of L-arginine plasma levels.
Plasma levels of TNFa, measured by ELISA, were also
significantly (P = 0.034) higher in patients with chronic renal
failure than in healthy volunteers (8.7 6.7 pg/mi, N = 7, vs.
3.2 2.1 pg/mI, N = 8).
Platelet NO synthesis
Figure 1 shows representative platelet aggregation (panel A)
and dose-response (panel B) curves to collagen in uremics and
controls. In both groups of subjects irreversible platelet aggre-
gation in response to collagen was obtained, but for uremics
concentrations significantly higher for the agonist than for
controls were required (TAC: 7.7 5.0 vs. 2.9 0.8 g/ml,
P = 0.030). Maximal amplitude of platelet aggregation curve in
response to collagen was lower in uremics than in controls,
possibly due to lower platelet number (uremic PRP: 2.0 0.6 x
l0 vs. control PRP: 3.9 1.1 x io platelets/j.d, P = 0.004).
Moreover, the dose of collagen which induced maximal re-
sponse was significantly higher in uremic than in control sub-
jects (uremic PRP: 17.3 6.0 vs. control PRP: 8.6 5.4 tg/mi,P = 0.034).
NO synthesis, evaluated as [3H]L-citrulline formation from
[3H]L-arginine, was negligible in unstimulated control platelets
(Fig. 2) and increased to a numerically modest but significant
extent (P <0.05) when platelets were exposed to collagen (Fig.
2). Uremic platelets even in basal conditions generated signifi-
cantly more NO than control platelets (P < 0.01, Fig. 2), but
after collagen stimulation a further significant increase in NO (P
<0.05 vs. basal, P < 0.01 vs. control) was documented (Fig. 2).
Generation of [3H]L-citrulline was completely abolished by the
addition of a specific inhibitor of the NO-synthase LNMMA
(300 jsM), suggesting that [3H]L-citrulline formation closely
reflected NO synthesis (data not shown). Intraplatelet levels of
cGMP, the NO second messenger, were numerically higher in
uremics than in controls, but differences were statistically
significant (P < 0.05 vs. controls) only for unstimulated plate-
lets (Fig. 2). A significant positive correlation, shown in Figure
3, was found between platelet NO and cGMP levels (r = 0.68,
P < 0.001).
Effect of uremic plasma on NO synthesis by endothelial cells
Human umbilical vein endothelial cells exposed to control
plasma generate NO as documented by the conversion of
[3H]L-arginine to [3H]L-citrulline (Fig. 4). When endothelial
cells in culture were exposed to uremic plasma, however, the
generation of NO significantly increased (P < 0.05 vs. HUVEC
exposed to control plasma; Fig. 4). Addition of endotoxin and
IFN7 to uremic plasma further increased NO synthesis to levels
that were remarkably higher than those recorded in HUVEC
exposed to control plasma containing the same amount of
stimulants (P < 0.01 vs. control plasma; Fig. 4).
Discussion
The first finding of the present study is that in patients with
chronic renal failure defective platelet aggregation is associated
with exaggerated platelet NO synthesis. These results extend to
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Fig. 1. Representative platelet aggregation (A) and dose-response (L
curves to collagen of control (•) and urernk (0)platelet rich plasma.
1 10
448 Noris et a!: Nitric oxide in uremia
humans previous observations made in uremic rats [4] and
indicate that NO may play a role in the abnormal hemostasis of
uremics. Nitric oxide interferes with primary hemostasis by
multiple pathways. It counteracts vessel injury-induced vaso-
constriction [22, 23], inhibits platelet adhesion to damaged
endothelium [8, 24] and interferes with the process of platelet-
platelet interaction [7] by activating soluble guanylate cyclase
that increases platelet cyclic GMP [7]. Enhanced platelet NO
synthesis suggested to us the theoretical possibility that sub-
stances are accumulating in uremic plasma that up-regulate
L-arginine nitric oxide signaling pathway. To explore such a
possibility, we have exposed human cultured endothelial cells
to uremic plasma. Our results documented that in this system
uremic plasma, unlike normal plasma, is a potent inducer of NO
formation. To try to clarify the mechanism(s) by which uremic
plasma enhances NO synthesis, we first explored the possibility
of an excessive substrate availability. Data of significantly
higher L-arginine levels in uremics as compared to healthy
volunteers, which confirmed previous reports [25—28], offered
an explanation for the increased NO synthesis in uremia. It has
been documented that the enzymes responsible for NO synthe-
sis constitute a family of at least two distinct types: a calcium-
dependent form which is constitutively expressed in brain [11]
and endothelial cells [9, 10], and a second type which can be
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Fig. 4. Conversion of [3H]L-arginine to [3HJL-citrulline by human
endothelial cells (HUVEC) exposed to control (0, N = 8)or uremic (,N = 7) plasma. Studies were performed in the absence (unstimulated)
or in the presence of LPS (1 tg/ml) and IFN y(150 U/mi). *p < 0.01,
°P C 0.05 vs. control plasma, °P C 0.05 vs. unstimulated. Data are
mean sD.
induced in endothelial cells and macrophages by cytokines [12]
and endotoxin [9, 13]. An increased substrate availability is not
expected to increase NO by up-regulating constitutive enzyme,
whose Km is about 2 /LM [11], and is therefore already saturated
by lower levels of L-arginine than are found in control plasma.
Rather, because of a Km around 30 LM [29] the inducible
NO-forming enzyme is actually dependent on the availability of
extracellular L-arginine. It is therefore conceivable that in
patients with high levels of L-arginine NO is formed in an
excessive amount due to activation of the inducible enzyme.
Moreover, high plasma levels of TNFa already reported in the
literature [30] and confirmed by the present data appear to be an
additional reason for enhanced formation of NO in uremia.
TNFa is increased in hemodialysis patients due to the reduced
renal clearance [31] concomitant with an enhanced monocyte
activation on dialysis membrane [32]. Recent evidence has been
provided that TNFa does not increase the constitutive NO-
forming enzyme activity [33] but is a potent inducer of the
inducible form of the enzyme in various cellular systems [17,
34, 35]. Thus, bovine aortic endothelial cells exposed to TNFa
release NO for a prolonged period, as documented by the
formation of L-['4C]citrulline from L-['4C]arginine [17]. More-
over, TNFa combined with IFN7 induces NO synthesis in
murine brain endothelial cells, the effect being abolished by the
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Fig. 2. Conversion of['HJL-arginine to
[5HJL-citrulline (A) and intracellular cyclic
OMP (B) in platelets from controls (0, N =
8) and uremics (0, N = 7). Data are from
resting (basal) and collagen-stimulated
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Fig. 3. Correlation between NO (measured as conversion of [3HJL-
arginine to [3H]L-citrulline) and cGMP levels in platelet rich plasma
from control and uremic subjects. r = 0,68; P C 0.001.
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protein synthesis inhibitor cycloheximide [121. The recent hy-
pothesis that TNFa mediates hemodialysis-associated hypoten-
sion [36, 37] is consistent with the possibility of a TNFa-
dependent excessive formation of NO by uremic vessels.
In additional experiments we have added to uremic plasma
LPS and IFNy, both of which are known to increase NO
synthase activity via the inducible enzyme [9]. Uremic plasma
enriched by LPS and IFNy markedly and significantly in-
creased NO synthesis as compared to normal plasma, to which
was added the same amount of LPS and IFN7. We have
interpreted these data to indicate that in uremia, exogenously
added LPS and IFNy synergize with endogenous TNFa in
up-regulating inducible NO synthase enzyme. Such a possibility
is in keeping with in vitro data [35] that TNFa and IFN7
synergize in enhancing NO synthesis by cultured endothelial
cells that reach values up to fifty times higher than those which
can be achieved by the use of each agent individually.
In conclusion, uremia appears to be a condition of excessive
NO which is most probably formed through the inducible
synthase enzyme. Enhanced NO biosynthesis may contribute
to uremic platelet dysfunction and possibly explain other man-
ifestations of the uremic syndrome such as hemodialysis hypo-
tension.
Our present results appear to conflict with a recent study [21]
showing that an endogenous inhibitor of NO synthesis, asym-
metrical dimethylarginine, accumulates in uremia. However,
concentration of this inhibitor in plasma of patients with chronic
renal failure is on average 4 tM, which is actually lower than
required to inhibit significantly either the constitutive or induc-
ible NO forming enzyme [21, 38]. Indeed, in the presence of
added 30 tmolIliter arginine, 5 mol/liter asymmetrical dimeth-
ylarginine inhibited macrophage NO synthase by only 17.6%,
and 3 /Lmol/liter caused a less than 4% increase in the tone of
pre-contracted endothelium-intact rat aortic rings [21].
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